A report on adherence with the new DOAC (Direct Oral Anticoagulants)
An update on the Watchman Device for LAA closure and Medicares CMS pathway toward procedure insurance reimbursement
An overview of the recent AF Symposium 2016 comprised of four key topics shared at the event
New insights on core mechanism behind AFIB
Update on Genetics and Fibrosis in AFIB
Anticoagulation update including imminent approval of a reversal agent for the Factor Xa inhibitor DOACs Eliguis, Xeralto and Savaysa
Wide spread adoption of Non-PV trigger/substrate ablation beyond a PVI/PVAI for more advanced cases of AFIB
Special Report FIRM mapping and ablation as of early 2016
And overview of FIRM as a proprietary Non-PV substrate mapping and ablation technology its promise and controversies.
An in-depth summary of the first FIRM-only ablation study of non-paroxysmal patients as part of the first prospective randomized control trial on FIRM technology.
Issue 141....December 2015/January 2016....17th Year